The SHAMAL study reveals that benralizumab, a biologic therapy, offers a new, safer approach to treating severe asthma without relying on high-dose steroids.
A landmark study has shown that severe asthma can be controlled using biologic therapies, without the addition of regular high-dose inhaled steroids which can have significant side effects.
The findings from the multinational SHAMAL study, published in DOI: 10.1016/S0140-6736(23)02284-5
The study was funded by AstaZeneca and carried out by researchers at renowned universities including Queens University Belfast, Université Paris-Saclay and Trinity College Dublin.